FDA lifts OncoMed partial hold

Share this article:

The FDA lifted its partial clinical hold on OncoMed's anti-Fzd7 vantictumab last week. The drug was being tested among non-small cell lung cancer chemotherapy patients, as well as patients with advanced HER2-negative breast cancer or advanced pancreatic cancer. The FDA froze the clinical trial in July over concern about “bone-related adverse events.”

Jefferies analyst Thomas Wei wrote in a Thursday research note that OncoMed expects to modify dosing regimens and enrollment criteria.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters